迈威生物

Mabwell (Shanghai) Bioscience Co., Ltd.
邁威(上海)生物科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2493)

PROPOSED CHANGE IN SCOPE OF BUSINESS, PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION AND REGISTRATION OF INDUSTRIAL AND COMMERCIAL CHANGES

The board of directors (the "**Board**") of Mabwell (Shanghai) Bioscience Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") announces that on August 30, 2026, resolutions in relation to proposed change in the scope of business, the proposed amendments to the articles of association of the Company (the **"Articles of Association**") and the registration of industrial and commercial changes were considered and approved, pursuant to which, the Company intends to put forward relevant proposals to the shareholders of the Company (the "**Shareholders**").

I. PROPOSED CHANGE IN SCOPE OF BUSINESS

In order to cater for the business development of the Group and to optimize the governance of the Company, the Board proposes to change the scope of business of the Company. The proposed amended scope of business will be: General items: technical services, technology development, technical consultation, technical exchange, technology transfer, technology promotion; medical research and experimental development; development of human genetic diagnosis and therapy technology; research and development and application of cell technology; leasing services (excluding leasing services subject to licensing); leasing of Class I medical equipment; leasing of Class II medical equipment; import and export of technology; import and export of goods; import and export of food; sales of Class I medical devices; sales of Class II medical devices; sales of foods for special medical purpose; food sales (sales of pre-packaged foods only); Internet sales (except for sales of goods requiring a license); agricultural scientific research and experimental development; corporate management consulting; information consulting services (excluding information consulting services subject to licensing). (except for projects that are subject to approval in accordance with the law, business activities shall be carried out independently in accordance with the law on the strength of the business license) Licensed items: production of drugs; commissioned production of drugs; production of pharmaceutical excipients; production of health food; production of food; wholesale of drugs; retail of drugs; sales of pharmaceutical excipients; production of foods for special medical purposes; sales of food; online sales of food; import and export of drugs. (For items subject to approval according to law, business activities may only be carried out after approval by relevant departments, and the specific business items shall be subject to the approval documents or license certificates of relevant departments).

The proposed change in the scope of business is subject to the fulfillment of the following conditions: (1) the Shareholders approving the change in the scope of business and the proposed amendments to the Articles of Association by way of a special resolution at an extraordinary general meeting of the Company (the "**EGM**"); and (2) the completion of the relevant approval, filing and/or registration procedures in China.

II. PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION

The Board proposes to amend the Articles of Association to reflect the change in the scope of business of the Company. The proposed amendments to the Articles of Association are subject to the approval by the Shareholders by way of a special resolution at the EGM, and will become effective upon the passing of the relevant special resolution at the EGM. Prior to the passing of the relevant special resolution at the EGM, the prevailing Articles of Association shall remain valid. Details of the proposed amendments are as follows:

Before proposed amendments	After proposed amendments
Article 15 As registered according to the laws, the Company's scope of business covers the following: General items: technical services, technical development, technical consulting, technical exchange, technical transfer, and technical promotion; medical research and experimental development; leasing services (excluding licensed leasing services); leasing of Class I medical devices; leasing of Class II medical devices; technology import and export; goods import and export; food import and export; sales of Class I medical devices; sales of Class II medical devices; sales of formula food for special medical purposes; food sales (limited to pre-packaged food only). (Except for items subject to approval in accordance with the laws, business activities may be carried out independently in accordance with the laws with the business license) Licensed items: pharmaceutical manufacturing; entrusted pharmaceutical manufacturing; production of pharmaceutical excipients; production of health foods; food production; pharmaceutical wholesale; pharmaceutical retail; sales of pharmaceutical excipients; production of formula food for special medical purposes; food sales; pharmaceutical import and export. (Items subject to approval in accordance with the laws may only be carried out upon the approval by the relevant authorities, and specific business activities shall be subject to the approval documents or permits issued by the relevant authorities)	Article 15 As registered according to the laws, the Company's scope of business covers the following: General items: technical services, technical development, technical consulting, technical exchange, technical transfer, and technical promotion; medical research and experimental development; **development of human genetic diagnosis and treatment technologies; R&D and application of cell-based technologies;** leasing services (excluding licensed leasing services); leasing of Class I medical devices; leasing of Class II medical devices; technology import and export; goods import and export; food import and export; sales of Class I medical devices; sales of Class II medical devices; sales of formula food for special medical purposes; food sales (limited to pre-packaged food only)**; Internet sales (excluding sales of goods requiring licenses); agricultural scientific research and experimental development; corporate management consulting; information consulting services (excluding information consulting services subject to licensing)**. (Except for items subject to approval in accordance with the laws, business activities may be carried out independently in accordance with the laws with the business license) Licensed items: pharmaceutical manufacturing; entrusted pharmaceutical manufacturing; production of pharmaceutical excipients; production of health foods; food production; pharmaceutical wholesale; pharmaceutical retail; sales of pharmaceutical excipients; production of formula food for special medical purposes; food sales; **online sales of food;** pharmaceutical import and export. (Items subject to approval in accordance with the laws may only be carried out upon the approval by the relevant authorities, and specific business activities shall be subject to the approval documents or permits issued by the relevant authorities)

III. CIRCULAR

The Company will propose special resolutions at the EGM for the Shareholders to consider and, if thought fit, approve the proposed change in the scope of business, proposed amendments to the Articles of Association and the registration of industrial and commercial changes.

A circular containing, among other things, details of the proposed change in the scope of business, proposed amendments to the Articles of Association and the registration of industrial and commercial changes, together with the notice of the EGM, is expected to be despatched to the Shareholders in a manner which the Shareholders have selected to receive corporate communications. A circular containing, among other things, further details of the above matters and the notice of the EGM has been published on the website of the Stock Exchange (http://www.hkexnews.hk) and the website of the Company (www.mabwell.com).

By Order of the Board
Mabwell (Shanghai) Bioscience Co., Ltd.
Dr. Liu Datao
Chairman of the Board and Executive Director

Shanghai, the PRC, August 30, 2026

As at the date of this announcement, the directors of the Company are: (i) Mr. Tang Chunshan, Dr. Liu Datao (Chairman of the Board), Dr. Wu Hai, Mr. Hua Jun and Dr. Gui Xun as executive directors; and (ii) Mr. Qin Zhengyu, Mr. Zhou Rui, Ms. Li Fan and Ms. Wang Fang as independent non-executive directors.